Treatment and prevention of cardiotoxicity due to anticancer therapy

Research output: Contribution to journalArticlepeer-review


Cardiotoxicity induced by anticancer treatment still remains an unanswered problem strongly affecting the quality of life and the overall survival of cancer patients. The most typical form of cardiotoxicity, a dilated cardiomyopathy, usually becomes manifest late in the course of the disease and it is classically considered to be refractory to therapy. Prevention of cardiotoxicity remains the most important strategy and several measures, including cardiac function monitoring, limitation of chemotherapy dose, use of anthracycline analogues and cardioprotectants, and early detection of cardiotoxicity by biomarkers, have been proposed. The response tomodern heart failure therapy of chemotherapy-induced cardiomyopathy has never been evaluated in clinical trials, and evidence-based recommendations for its treatment are still lacking. Although it is likely that angiotensinconverting- enzyme inhibitors and beta-blockers, used for other forms of cardiomyopathy may be highly effective also in this setting, there is still some unjustified concern to use them in asymptomatic cancer patients, and current management mainly focuses on treatment of only symptomatic patients.

Original languageEnglish
Pages (from-to)92-100
Number of pages9
JournalJournal of Cardiovascular Echography
Issue number2
Publication statusPublished - 2011


  • Cardiotoxicity
  • Chemotherapy-induced cardiomyopathy
  • Prevention
  • Treatment
  • Troponin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Treatment and prevention of cardiotoxicity due to anticancer therapy'. Together they form a unique fingerprint.

Cite this